News | Radiation Therapy | April 16, 2020

Funding continues momentum of recent FDA clearance and first system order

Funding continues momentum of recent FDA clearance and first system order

April 16, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer, today announced the close of a $100 million equity financing led by Public Sector Pension Investment Board (PSP Investments), one of Canada’s largest pension investment managers that focuses on long-term investments with partners demonstrating strong value orientation strategies.

“RefleXion’s bold vision for the future of cancer care stands to completely reshape how physicians think about treating patients with stage 4 cancer,” said Loïc Julé, managing director, Global Investment Partnerships Portfolio, PSP Investments.“This is exactly the mindset of companies we strive to build long-term relationships with. We are thrilled to support RefleXion during this next phase of their growth as they ramp up market and clinical adoption of this groundbreaking technology.”

RefleXion’s existing investors, TPG’s The Rise Fund, KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, and global pharmaceutical leaders, Pfizer Ventures and Johnson & Johnson Innovation, JJDC Inc., all participated in the round. BofA Securities and Morgan Stanley & Co., LLC acted as placement agents for the company.

“This new influx of capital continues our momentum initiated first by FDA clearance of the RefleXion X1 platform last month, then quickly followed by the close of our first system order at one of the world’s leading cancer centers,” said Todd Powell, president and CEO of RefleXion. “The support of this top-tier investment syndicate enables us to further scale operations around commercializing the X1 platform.

“Moreover, these funds allow us to validate the practical implications of using BgRT on a daily basis as we transform radiotherapy from early-stage cancer treatment to an option for patients with all stages of cancer,” continued Powell.

The RefleXion X1 machine with BgRT is designed to overcome the technical limitations that currently restrict radiotherapy to one or two tumors. When available, RefleXion will scale BgRT to treat all visible tumors, even those that move rapidly due to bodily functions such as breathing or digestion, in the same treatment session.

RefleXion recently announced  FDA clearance for stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT), and its first clinical and commercial client.

For more information: www.reflexion.com/


Related Content

News | Stereotactic Breast Imaging

January 27, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), both ...

Time January 27, 2023
arrow
Feature | Radiology Imaging | By Melinda Taschetta-Millane

Have you read the January/February 2023 issue of Imaging Technology News? If not, take some time out of your busy ...

Time January 24, 2023
arrow
News | Breast Imaging

January 24, 2023 — For patients with cancer, lengthy delays in treatment can decrease their chances of survival. In an ...

Time January 24, 2023
arrow
News | Artificial Intelligence

January 23, 2023 — PreciseDx, a leading innovator in AI-powered, patient-specific disease analysis, announced its recent ...

Time January 23, 2023
arrow
Feature | Lung Imaging | By Christine Book

In this third in the three-part Special Report, the ITN editorial team offers the most current information on reported ...

Time January 17, 2023
arrow
Feature | Lung Imaging | By Christine Book

New for 2023, in each issue, Imaging Technology News (ITN) will profile a leader in radiology to share insight, updates ...

Time January 16, 2023
arrow
Feature | ASTRO | Christine Book

The Imaging Technology News (ITN) editorial team is pleased to present the second portion of the American Society for ...

Time January 13, 2023
arrow
News | Proton Therapy

January 13, 2023 — RaySearch Laboratories AB announces that The Ohio State University Comprehensive Cancer Center - ...

Time January 13, 2023
arrow
News | Proton Therapy

January 9, 2023 — RaySearch Laboratories AB announced that CGN Medical Technologies has in December 2002 placed an order ...

Time January 08, 2023
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

As 2022 comes to a close, the Imaging Technology News team takes a look at the year's most viewed content. Here is a ...

Time January 02, 2023
arrow
Subscribe Now